Importantly, however, our study includes quite recent patients and the treatment paradigms of HER2-positive breast cancer have been evolving in the last years with introduction of new HER2 antibodies and antibody-linked cytotoxic payloads and older studies might not capture the effects of these treatments. This evidence concerns the gene ERBB2 and breast cancer.